Investors of Soleno Therapeutics, Inc. Encouraged to Join Securities Fraud Class Action

Soleno Therapeutics, Inc.: A Call to Action for Shareholders

Recent developments concerning Soleno Therapeutics, Inc. (NASDAQ: SLNO) have raised significant alarms for investors who experienced losses related to the company. The Law Offices of Frank R. Cruz have announced an opportunity for these shareholders to take a pivotal role in a securities fraud class action lawsuit.

Background of the Lawsuit

Between March 26, 2025, and November 4, 2026, numerous claims have surfaced urging that the company failed to disclose critical information regarding its Phase 3 clinical trials for DCCR (the drug aimed at treating hyperphagia in individuals with Prader-Willi Syndrome). Specifically, the allegations indicate that Soleno failed to adequately inform investors about safety concerns related to fluid retention issues in clinical trial participants, effectively misrepresenting the drug's safety profile.

Moreover, the lawsuit contends that DCCR posed greater safety risks than what the company had acknowledged. Due to these oversights, investors were led to believe in the drug's commercial viability, which may have been significantly lower than disclosed. The implications of these allegations are far-reaching, as they suggest a series of misleading claims regarding the company's operations and future projections.

Implications for Shareholders

For shareholders who endured financial losses due to these alleged discrepancies, this lawsuit offers a chance to reclaim some of their losses. If you are among those affected, it is crucial to act promptly. The deadline to participate as a lead plaintiff is May 5, 2026. Interested parties are invited to engage, and they do not need to take immediate action to be part of the lawsuit. Connecting with legal counsel or simply remaining an absent member of the class action is permissible.

Participants looking to join the lawsuit can contact the Law Offices of Frank R. Cruz through the specified email or phone number. Inquiries should include pertinent personal details, such as your mailing address, telephone number, and the number of shares purchased.

This class action lawsuit stands as a pivotal moment for investors seeking accountability from Soleno. The Law Offices of Frank R. Cruz are committed to representing those who feel misled by the company's previous statements regarding its clinical endeavors and business practices.

Next Steps for Investors

If you're a shareholder wishing to learn more about your rights in this class action, you should promptly reach out to the Law Offices of Frank R. Cruz. Timely action may be essential to your potential recovery. While there’s no immediate need for action, staying informed is imperative in navigating these complex proceedings. Follow the firm's updates and stay engaged through their social media channels for the latest developments.

In summary, shareholders of Soleno Therapeutics, Inc. have the opportunity to seek justice and potential recovery through this class action lawsuit due to significant allegations of securities fraud. Don’t miss your chance to act.

Final Thoughts

The path ahead may seem daunting, but collective efforts can lead to meaningful resolutions. Your participation could not only bolster your own stakes but also empower fellow investors who find themselves in a similarly challenging position. It’s a powerful reminder of the importance of transparency and accountability in the corporate world.